ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of “Moderate Buy” by Analysts

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has been assigned an average rating of “Moderate Buy” from the sixteen research firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $25.60.

ACAD has been the subject of several recent research reports. Raymond James reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Finally, StockNews.com cut ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th.

ACADIA Pharmaceuticals Stock Down 4.2 %

Shares of NASDAQ ACAD opened at $17.26 on Friday. The firm’s 50-day simple moving average is $15.96 and its 200 day simple moving average is $16.14. The company has a market cap of $2.87 billion, a price-to-earnings ratio of 22.13 and a beta of 0.40. ACADIA Pharmaceuticals has a 12-month low of $14.15 and a 12-month high of $32.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.06. The business had revenue of $250.40 million for the quarter, compared to the consensus estimate of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm’s quarterly revenue was up 18.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.40) EPS. On average, equities analysts expect that ACADIA Pharmaceuticals will post 0.73 earnings per share for the current year.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,073 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the transaction, the insider now owns 19,863 shares of the company’s stock, valued at $333,897.03. This represents a 17.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Brendan Teehan sold 10,329 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $173,630.49. Following the transaction, the chief operating officer now directly owns 62,105 shares of the company’s stock, valued at approximately $1,043,985.05. This trade represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,661 shares of company stock valued at $414,551 in the last quarter. 28.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several large investors have recently made changes to their positions in ACAD. Park Place Capital Corp acquired a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Values First Advisors Inc. acquired a new stake in shares of ACADIA Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Quest Partners LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 1,047 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in shares of ACADIA Pharmaceuticals in the 2nd quarter valued at approximately $81,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ACADIA Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 1,066 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.